News

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Strengthens Clinical Operations Capabilities with The Acquisition of Topstone Research

October 1, 2018

Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma

Read More

Veristat Congratulates Agios on the FDA Approval of TIBSOVO®

August 16, 2018

 The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation

 

SOUTHBOROUGH, MA –  August 16, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test.

Read More

Veristat’s Collaboration with Aegerion Contributes to FDA Approval of Juxtapid™

March 20, 2013

Veristat’s Strategic Guidance Contributes to Successful Approval of Aegerion’s Novel Drug Juxtapid

 

Read More